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Abstract: Nanoscale drug carriers have been extensively developed to improve drug therapeutic 
efficiency. However, delivery of chemotherapeutic agents to tumor tissues and cells has not been 
favorably managed. In this study, we developed a novel “intelligent” nanoparticle, consisting 
of a gelatinase-cleavage peptide with poly(ethylene glycol) (PEG) and poly(ε-caprolactone) 
(PCL)-based structure for tumor-targeted docetaxel delivery (DOC-TNPs). The docetaxel-loaded 
PEG-PCL nanoparticles (DOC-NPs) that did not display gelatinase-stimuli behaviors were used 
as a control. We found clear evidence that the DOC-TNPs were transformed by gelatinases, 
allowing drug release and enhancing the cellular uptake of DOC (P , 0.01). In vivo biodistri-
bution study demonstrated that targeted DOC-TNPs could accumulate and remain in the tumor 
regions, whereas non-targeted DOC-NPs rapidly eliminated from the tumor tissues. DOC-TNPs 
exhibited higher tumor growth suppression than commercialized Taxotere® (docetaxel; Jiangsu 
Hengrui Medicine Company, Jiangsu, China) and DOC-NPs on hepatic H22 tumor model via 
intravenous administration (P , 0.01). Both in vitro and in vivo experiments suggest that the 
gelatinase-mediated nanoscale delivery system is promising for improvement of antitumor 
efficacy in various overexpressed gelatinase cancers.
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Introduction
Active targeting delivery systems have become a large area of focus in cancer 
therapeutics. Targeting ligands, such as aptamer,1 RGD peptide,2 antibody,3 folate,4 
are peripherally conjugated to nanocarriers for binding to particular receptors 
overexpressed by tumor cells or vasculatures. However, much ligand-targeted 
therapeutics is only effective in certain types of cancer cases. For example, the anti-
HER2 antibody delivery system only increased the therapeutic index in HER2 positive 
tumor.5 Another new targeting strategy in development is employing stimuli-sensitive 
nanocarriers, such as thermo-sensitive micelles,6 magnetic nanoparticles,7 and photo-
responsive polymers.8 The structures of these nanocarriers could be transformed by 
external or internal triggering elements, facilitating drug release from nanoparticles 
or interacting with the tumor cells targetedly.9 Although these reported nano-drugs are 
sensitive enough in laboratory research, limitations for clinical applications still exist. 
For instance, the thermo-responsive or magnetic nanocarriers need external heating or 
magnets to guide nanoparticles to the tumors, so the tumor locations should be clear and 
definite before treatment. As a result, treatment of disseminated tumors, which are an 
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obstacle of clinical therapeutics, is a great challenge for these 
stimuli-responsive nanocarriers.10 Therefore, exploration of 
more universal and targeted delivery systems is necessary 
for cancer therapy.
Proteases, which can recognize and hydrolyze   peptide 
substrates, are one of the most promising triggers for 
stimuli-responsive drug delivery.11 Considerable efforts 
have been made to develop protease-targeted drugs and 
have   demonstrated promising results.12 For example, in vitro 
experiments, the esterase and phospholipase A2 activated 
strategies have been developed to improve intercellular 
uptake efficacy.13,14 However, the environment in vivo is 
much more complex than that during in vitro experiments. 
So, it is not surprising that although some protease-stimuli 
strategies work effectively in vitro, the in vivo results are 
disappointing. In general, pervasiveness and selectivity 
of targeted proteases are two primary factors affecting the 
results of in vivo experiments.
Matrix metalloproteases (MMPs) have received great 
attention in cancer research due to their important role in 
cancer progression.15 Notably, MMPs are a large family of 
enzymes with different groups of MMPs playing different 
roles in cancer progression. Some MMPs, such as MMP12, 
might help defy cancers.16 Presently, many functions of 
MMPs are still unknown. Loss of selectivity for specific 
MMPs might induce side effects. Among various tumor-
associated MMPs, gelatinases (MMP2/9, Collagenases IV) 
are known to be abundantly present in most tumors and their 
basic function is to degrade the extracellular matrix (ECM). 
Many studies have verified that gelatinases are ‘bad’ MMPs, 
playing an important role in numerous malignant tumor 
behaviors, such as angiogenesis, apoptosis, aggressiveness, 
metastasis, and poor survival.17,18 Therefore, gelatinases may 
be suitable candidates for stimuli-responsive targeted strate-
gies, although MMP-stimuli strategies have been applied to 
prodrugs,19 and liposomes.20,21 Nanoparticles, which have 
their own advantages on drug delivery, using such strategies 
are rare. Some gelatinase-mediated drug delivery strategies 
do not pay attention to the different roles of MMP subtypes, 
which are directly related to the therapeutic effects. There-
fore, we developed the gelatinase-stimuli nanoparticle for 
the improvement of anticancer efficacy.
We focus on the enzyme-stimuli strategy also because 
PEGylated nanoparticles have some shortcomings. The 
PEGylated nanoparticles are primarily unable to interact 
with tumor cells thoroughly, leading to decreased efficacy 
and damage to normal cells. The gelatinase-stimuli nano-
particles can strike a balance between PEGylation and 
dePEGylation (Figure 1). The PEG outer shell provides 
nanoparticles with stealth and increases their blood circulat-
ing time. Once the nanoparticles accumulate in the tumors, 
the peptides are degraded by gelatinases. The PEG blocks are 
cleaved, and the remaining PCL blocks aggregate, resulting 
in PEG-uncoated nanoparticles being retained in the tumor 
region, efficiently reaching more tumor cells, and presenting 
high antitumor activity. Additionally, the carriers can easily 
deform without entering cells, because active gelatinases are 
secreted exogenously.
In the present study, the poly(ε-caprolactone) (PCL) 
  polymer was chosen because of its excellent biocompatibility 
and biodegradability properties. To emphasize the superiority 
of this novel nanocarrier, we used the well-recognized, 
  effective carriers, PEG-PCL nanoparticles as a positive 
  control. We confirmed the specific gelatinase-responsive 
  profile from physicochemical characterization, in vitro   cellular 
uptake, and in vivo real-time near-infrared fluorescent (NIRF) 
imaging. Further, we assessed the anticancer superiority of 
DOC-TNPs by tumor volume observation, historical study, 
positron emission tomography, and computed tomography 
(PET/CT) real-time scanning on murine hepatic H22 tumor-
bearing mice as a model for comparison to Taxotere® and com-
mon DOC-NPs through intravenous (IV) administration.
Materials and methods
Materials
Methoxy-polyethyleneglycol-NHS (mPEG-NHS) was 
  purchased from Beijing Jiankai Technology Co, (Beijing, 
China). The gelatinase-cleavable peptide (PVGLIG) was 
obtained from Shanghai HD Biosciences Co (Shanghai, 
China). Docetaxel (DOC) and Taxotere® (Taxotere® is the 
commercial name of DOC) were provided by Jiangsu   Hengrui 
Medicine Company (Jiangsu, China). Coumarin-6 and 
Active gelatinase
PEG block
Gelatinase
PCL block
Docetaxel
Gelatinase cleaved peptide
Cancer cell
Figure 1 The gelatinase-stimuli strategy enhanced nanoparticles interactions with 
cancer cells in the tumor tissues. After release from tumor capillaries, the PEG-
Pep conjugates were cleaved by gelatinases, which were specifically secreted in 
the tumor microenvironment. The remained PCL blocks aggregated and the PEG-
uncoated PCL nanoparticles interacted efficiently with cancer cells, resulting in fast 
drug release and effective therapeutics.
Abbreviations: PEG, poly(ethylene glycol); PCL, poly(ε-caprolactone); Pep, peptide.
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gelatinases were purchased from Sigma-Aldrich® (St Louis, 
MO). ε-caprolactone (ε-CL) and dimethyl   formamide (DMF) 
were purified by being dehydrated over CaH2 at room tem-
perature and distillated under reduced pressure. All other 
chemicals were used as received without further treatment.
Synthesis of PEG-Pep-PCL copolymers 
and PEG-Peptide conjugates
The mPEG-NHS (200 mg) and peptides (26 mg) were 
  dissolved in DMF (3 mL) containing 3% Et3N and stirred 
for 3 hours at room temperature to prepare PEG-Peptide 
conjugates. The unconjugated peptides were removed by 
dialysis in a 3500 Da MWCO membrane (Sigma-Aldrich) 
against deionized water for 24 hours.
Synthesis of PCL-NH2 polymers
A polymerization tube containing ε-CL and L-leucine was 
vacuated and sealed off. The polymerization was carried 
out at 160°C for 24 hours. Then the resulting complexes 
were dissolved in dichloromethane (DCM) and precipitated 
into a large amount of cold ethyl ether to produce PCL-
COOH. The DMF dissolved PCL-COOH polymers were 
added with 4-dimethylamiopryidine (DMAP), 1-ethyl-3-[3-
dimethylaminopropyl] carbodimide hydrochloride (EDC), 
ethylenediamine and N-hydroxysulfosuccinimide sodium salt 
(NHS), and stirred at 37°C for 18 hours. The mixture was 
precipitated in ethanol, filtered through medium speed filter 
paper, and dried under vacuum to prepare the PCL-NH2.
Synthesis PEG-Pep-PCL and PEG-PCL 
copolymers
The mixture of PCL-NH2 (0.002 mol), PEG-Peptide 
  conjugates (0.002 mol), DMAP (0.003 mol), EDC 
(0.002 mol) and NHS (0.002 mol) in DMF was stirred for 
24 hours at 32°C. The crude PEG-Peptide-PCL copolymers 
were purified by dialysis (MWCO 13 kDa) for 24 hours, 
lyophilized to powder, and stored at 4°C for further use. The 
PEG-PCL di-block copolymers were synthesized by a ring 
opening copolymerization as we previously described.22
Preparation of DOC-loaded 
nanoparticles
DOC-loaded nanoparticles were prepared by a modified 
nano-precipitation method.23 Briefly, 20 mg of copolymers 
and 10 mg of DOC were dissolved in 0.2 mL hot acetone by 
heating to 60°C. Subsequently, the mixture was added into 
6 mL water quickly to form nanoparticles. The remaining 
acetone was removed by rotary vacuum evaporation. The 
resultant solution was filtered to remove non-incorporated 
DOC and the suspension was freeze-dried for further use. 
The empty nanoparticles were prepared similarly in the 
absence of DOC.
Particle size and morphology  
of the particles
The particle size and polydispersity of PEG-Pep-PCL and 
PEG-PCL nanoparticles were measured by dynamic light 
scattering (DLS) (Brookhaven Instruments Corporation, 
NY). The values were the average of triplicate measurements 
for a single sample.
PEG-Pep conjugates cleavage  
in response to gelatinases
We then investigated the cleavage of PEG-Pep conjugates 
in the presence of gelatinases. PEG-Pep-PCL nanoparticles 
(0.25 mM) were incubated in PBS solution with or without 
gelatinases at 37°C for 24 h. The morphology of the nano-
particles was determined by scanning electron microscopy 
(SEM) (S-4800, HITACHI, Tokyo, Japan).
In vitro DOC release from  
the nanoparticles
Twenty-five milligram lyophilized DOC-loaded nanoparticles 
were redispersed in 1 mL of phosphate buffer solution (PBS, 
0.01 M, pH 7.4) with or without 1 mg/mL gelatinases and 
put into a dialysis bag (MWCO 12 kDa). The dialysis bag 
was immersed into 5 mL release medium (PBS containing 
0.1% v/v Tween 80® [Sigma-Aldrich]) with gentle agitation 
at 37°C for 96 hours.24 At different time points, the release 
medium was withdrawn for HPLC analysis, and equivalent 
release medium was added.
In vitro cell uptake assays
Human colon cancer carcinoma cell line LOVO, human Lewis 
lung carcinoma (LLC), and murine hepatic   carcinoma cell 
line H22 were purchased from Shanghai   Institute of Cell Biol-
ogy (Shanghai, China). The tumor cells were routinely cul-
tured in RPMI 1640 medium (Sigma-  Aldrich), supplemented 
with 10% fetal bovine serum (FBS) at 37°C. The gelatinase-
stimuli property and biocompatibility of nanoparticles were 
confirmed by in vitro cellular uptake study. We measured the 
gelatinases expressions of different adherent cancerous cells 
by gelatin zymography (see “Supplemental data”). The colon 
carcinoma cells LOVO and Lewis lung cancer cells were cho-
sen for their different gelatinases levels. 105 LOVO and LLC 
cells were seeded in 30-mm Petri dishes and incubated with 
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500 µL medium containing coumarin-6 loaded nanoparticles 
(6.25 µg/mL calculated by coumarin-6) for 2 hours at 37°C. 
Then the media were replaced with fresh cell culture media 
and the fluorescent signals of cells were imaged using the 
laser scanning confocal microscopy (LSM710, Carl Zeiss 
MicroImaging GmbH, Berlin, Germany) with an excitation 
wavelength of 460 nm.
We also carried out the cellular uptake studies on 
  suspended cells H22. The particles were labeled with Rho-
damine B isothiocyanate, which  was reacted with hydroxyl 
end group of PCL block in PEG-Pep-PCL copolymers. 
Briefly, 1 mg Rhodamine B isothiocyanate and 30 mg PEG-
Pep-PCL copolymers were dissolved in 3 mL DMF, and the 
system was allowed to react for 10 hours. After which, the 
Rhodamine B-labeled PEG-Pep-PCL nanoparticles were 
purified by dialysis against deionized water for 48 hours. The 
Rhodamine B-labeled PEG-PCL nanoparticles were prepared 
in the same way. The H22 cell uptake studies were taken in 
the above mentioned way. The quantitative study was also 
carried out as we previously described.25 Briefly, H22 cells 
were seeded in a 96-well black plate at a density 1 × 104 cells 
per well. Coumarin-6 loaded Rhodamine B-labeled PEG-Pep-
PCL and PEG-PCL nanoparticles (6.25 µg/mL calculated 
by coumarin-6) were added into the cultured medium and 
incubated for 0.5, 1, 2, and 4 hours at 37°C. At different time 
points, the cells were collected by centrifugation, washed 
three times by PBS and lysed by 200 µL cell lysis buffer 
(50 mM Tris-HCl pH 7.4,150 mM NaCl, 1% Triton X-100). 
The fluorescence of whole cell lysate was determined by a 
fluorescence microplate reader (Safire, Tecan, Männedorf, 
Switzerland). The excitation and emission wavelength was 
460 nm and 500 nm for coumarin-6, respectively. The cell 
uptake efficiency can be calculated by this equation:
  Uptake efficiency (%) =
(I I)
(I I
sample negative
positiven egativ
−
− e
e
)
× 100%
The Isample, Ipositive and Inegative are the fluorescence 
intensities of the sample, positive control and negative 
control, respectively. In these tests, particle suspension 
was added to five wells as the positive control. In contrast, 
the negative control refers to the nanoparticles without 
coumarin-6 that were added in wells with cells.
Real-time NIRF imaging
In vivo distribution of nanoparticles was studied by NIR-
797 labeled nanoparticles. PEG-PCL or PEG-Pep-PCL 
nanoparticles were labeled with NIR-797-isothiocyanate 
(Sigma-Aldrich). Briefly, 2 mg NIR-797-isothiocyanate and 
200 mg PEG-Pep-PCL were dissolved in 4 mL anhydrous 
DMF for 18 hours with agitation. After the reaction, uncon-
jugated NIR-797 was removed by dialysis (MWCO 3000 Da) 
for 2 days. The NIR-797-labeled PEG-PCL nanoparticles 
were prepared in the same way and lyophilized for further 
use. 107 H22 tumor cells were inoculated subcutaneously into 
the right axilla of ICR mice (18–22 g, 4–5weeks, male) to 
establish the tumor model. The NIR-797 labeled PEG-PCL 
and PEG-  Pep-PCL nanoparticles (equivalent to the dose DOC 
10 mg/kg) were tail vein injected into H22 tumor bearing 
mice (the same tumor model as that in the antitumor study) 
on the seventh day after inoculation. The time-dependent 
biodistribution in mice was imaged by the Maestro™ in-vivo 
imaging system (CRi Inc, Woburn, MA) at 1, 2, 4, 12, 24, 
48, and 72 hours after intravenous administration.
In vivo antitumor efficacy of DOC-loaded 
nanoparticles
All animal studies were performed in compliance with 
guidelines set by the Animal Care Committee at Drum Tower 
  Hospital, Nanjing, China. ICR mice (18–22 g, 4–5 weeks, 
male) were inoculated with 107 H22 cells subcutaneously 
on the right axilla. Tumor dimensions were measured with 
vernier calipers and the volumes were calculated as follows: 
tumor volume (mm3) = width2 × length/2. When the tumors 
reached 100 mm3 (designated as day 1), the animals were 
randomized into the following treatment groups: saline 
(0.5 mL), empty NPs, empty TNPs, Taxotere® (10 mg/kg), 
DOC-NPs (10 mg/kg DOC equal), and DOC-TNPs (10 mg/
kg DOC equal). For the treatment, 0.5∼0.6 mL of different 
DOC formations and empty nanoparticles dissolved in saline 
were intravenously administered into the mice every 6 days, 
three times per day. On day 21 after the first treatment, the 
tumor tissues from each group were dissected and fixed in 
10% neutral buffered formalin. The tumor paraffin slices 
with a thickness of 5 µm were stained with hematoxylin 
and eosin (H&E).
In vivo PET/CT imaging
A combined PET/CT scanner (Gemini GXL, Philips, 
  Amsterdam, The Netherlands) was used to estimate the 
early antitumor efficacy on Day 7 after DOC   administration. 
After anesthesia with pentobarbital sodium (40 mg/kg), 
the H22 bearing mice that received Taxotere®, DOC-NPs, 
and DOC-TNPs were tail vein injected with approximately 
100 µCi/0.3 mL fluorin-18-2-fluoro-2-deoxy-d-glucose 
(18F-FDG) as radiotracer. PET and CT images were   collected 
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in the prone position 30 minutes after injection. The standard 
uptake values (SUVs) in regions of interests (ROIs) were cal-
culated by the following equation:
  SUVs =
Radioactivity concentration in ROIs [ i/cc] 
Injected
µC
   dose [ i/cc] Animal weight [g] µC ×
Statistical analysis
The ANOVA and student’s t-test (two tailed) were used for 
statistical analyses. P-values less than 0.05 were considered 
statistically significant.
Results
Characterization of PEG-Pep-PCL 
nanoparticles
We synthesized the PEG-Pep-PCL copolymers via ring-
opening copolymerization and amidation (Figure S1 in 
“Supplemental data”). Comparing the 1H NMR of PEG-
Pep-PCL and PEG-PCL copolymers, the proton signal 
from methyl groups in the peptide (0.823–1.006 ppm) 
demonstrated that the specific substrates of gelatinases were 
successfully inserted into the intermediate of PEG and PCL 
blocks (Figure S2 in “Supplemental data”). The diameter of 
DOC-TNPs was about 85.7 nm measured by DLS and the 
polydispersity index was 0.131. The drug loading content was 
20.3% and drug encapsulation efficiency was 80.7% with the 
initial feed amount of [DOC/nanoparticles] = 1:2 (Table S1 in 
  “Supplemental data”). DOC-NPs were   prepared as a control 
to investigate the carriers’ property and intracellular uptake.
The SEM images verified the response of DOC-TNPs to 
gelatinases. As shown in Figure 2A(a), the DOC-TNP was a 
monolayer spherical particle with a diameter of approximately 
60 nm, which was smaller than the size obtained by DLS due 
to the shrinking in dry state. Such size ranged nanoparticles 
appreciably accumulate in tumors due to the EPR effect. After 
co-incubation with gelatinases for 24 hours, the nanoparticles 
aggregated (Figure 2A(b)) and the diameters significantly 
increased. In addition, these reunited nanoparticles did not 
break up and still kept the spherical shape.
In vitro DOC release from DOC-loaded 
nanoparticles
To evaluate the diffusion of DOC from the inner core of 
nanoparticles in the presence of gelatinases, DOC-TNPs and 
DOC-NPs were incubated in release medium with or without 
gelatinases. Both nanoparticles exhibited a steady continued-
release pattern with a certain amount of initial burst release 
and a sustained release in the following time in the absence of 
gelatinases (Figure S3 in “Supplemental data”). The release 
of DOC from DOC-TNPs exhibited faster release than that of 
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Figure 2 The gelatinase-stimuli characterization of PEG-Pep-PCL nanoparticles. (A) SEM images of PEG-Pep-PCL nanoparticles in response to gelatinases (a) PEG-Pep-PCL, 
(b) PEG-Pep-PCL co-incubation with gelatinases. (B) In vitro release of DOC from the nanoparticles in the presence of gelatinases. (C) The cellular uptake of coumarin-6-
loaded PEG-PCL and PEG-Pep-PCL nanoparticles in two kinds of cancer cells, which express different gelatinases levels (LOVO cells expressed relatively high gelatinases 
compared with LLC cells).
Abbreviations: DOC, docetaxel; LLC, Lewis lung carcinoma; PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide; SEM, scanning electron microscope.
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The intracellular uptake was also carried out on sus-
pended cells H22, which highly expressed gelatinases 
(Figure S5 in “Supplemental data”). The nanoparticles 
were marked with Rhodamine B isothiocyanate to track 
the position of nanoparticles. Insoluble dye, coumarin-6, 
dispersed evenly in particles to imitate the actions of DOC. 
Figure 3A demonstrates that the green fluorescence from 
coumarin-6 and red color from Rhodamine B labeled nano-
particles were overlapped in the cytoplasm, suggesting that 
coumarin-6 entered cytosol together with nanoparticles. 
Besides the fluorescence densities of the PEG-Pep-PCL 
nanoparticles, treated groups were always higher than that 
of PEG-PCL nanoparticles, illustrating that PEG-Pep-PCL 
nanoparticles entered the cancer cells more efficiently. To 
confirm this supposition, the fluorescence microplate reader 
was used to quantify the cellular uptake efficiency, the ratio 
between the amounts of coumarin-6 loaded nanoparticles 
taken up by cells with the total amount. The uptake effi-
ciency increased over the course of 4 hours, and a higher 
cell internalization of PEG-Pep-PCL nanoparticles was 
observed. Statistically, compared to PEG-PCL nanopar-
DOC-NPs in gelatinases solution (19% versus 14% at 1 hour, 
and 82% versus 64% at 96 hours [Figure 2B]).
In vitro cellular uptake studies
We next examined whether or not the cellular uptake 
efficiency of PEG-Pep-PCL nanoparticles depended on 
the gelatinase levels. For this purpose, we first quantified 
the active gelatinases via gelatin zymography to screen 
suitable cancer cells (Figure S4 in “Supplemental data”). 
Colon carcinoma cells LOVO expressing high gelatinase 
levels were used as a positive control for comparison with 
the Lewis lung cancer cells, which express relatively low 
gelatinases compared to LOVO cells. The fluorescence 
intensity of PEG-PCL in LOVO cells is weaker than LLC, 
while the fluorescence intensity of PEG-Pep-PCL in LOVO 
cells is similar to LLC (Figure 2C). The enhanced cellular 
uptake of coumarin-6-loaded PEG-Pep-PCL nanoparticles 
to PEG-PCL nanoparticles was found in both LLC and 
LOVO cells, and the fluorescence difference was more 
distinguished in LOVO cells, which relatively express more 
active gelatinases.
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Figure 3 The in vitro H22 cellular uptake studies of nanoparticles. (A) Confocal microscopy images of H22 cells after incubation with coumarin-6-loaded Rhodamine-B 
labeled PEG-PCL and Rhodamine-B labeled PEG-Pep-PCL nanoparticles. (B) The uptake efficiencies of coumarin-6-loaded PEG-PCL and PEG-Pep-PCL nanoparticles at 
different time points. 
Notes: **P , 0.01; ****P , 0.0001.
Abbreviations: PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide.
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ticles, the cellular uptake of PEG-Pep-PCL (0.5 hours, 
P , 0.01; 2 hours, P , 0.0001; 4 hours, P , 0.01) clearly 
showed this trend (Figure 3B). Especially at 2 hours where 
the cellular uptake of PEG-  Pep-PCL was 159.55% higher 
than that of PEG-PCL.
The real-time biodistribution in tumor 
bearing mice and in vivo antitumor effect 
of nanoparticles
The real-time biodistribution of two nanoparticles in 
H22 tumor bearing mice was measured by a non-invasive 
near-infrared fluorescence imaging owing to dye-labeled 
PCL chain ends. Figure 4 depicts the NIRF dye NIR-797 
labeled DOC-TNPs and DOC-NPs in vivo distribution dur-
ing 72 hours. One hour after IV injection, the   fluorescence 
signals of DOC-TNPs were found in the tumor regions, 
however, the same signals were mostly observed on the abdo-
men, indicating a fast hepatobiliary excretion tract. As time 
went on, the abdomen NIR fluorescence   signals decreased, 
while the tumor signals became higher. Interestingly, the 
increasing NIR fluorescence densities of tumor zones were 
not observed in the DOC-NPs treated mice. Furthermore, 
at 48 hours post-injection, few fluorescence signals from 
PEG-PCL could be observed, suggesting a large amount of 
PEG-PCL nanoparticles were eliminated from the body. The 
fluorescence signals of PEG-Pep-PCL group in the tumor 
regions of DOC-TNPs were always stronger than the signals 
of the DOC-NPs group during the whole 72 hours, suggest-
ing that DOC-TNPs preferred to concentrate and retain in 
the tumor regions. NIR fluorescence signals were clearly 
observed for NIR-797 labeled PEG-PCL nanoparticles, 
which were likely mediated by the enhanced permeability 
and retention (EPR) effect and the stealth effect afforded 
by PEGylation.
The in vivo antitumor studies of DOC-TNPs were 
  performed on H22 tumor bearing mice, which highly 
expressed gelatinases. DOC-TNPs were given by intrave-
nous administration every sixth day for 21 days. Saline, 
empty PEG-PCL nanoparticles, empty PEG-Pep-PCL 
nanoparticles, Taxotere®, and DOC-NPs were also given 
as controls for comprehensive comparison. On day 21 after 
the first treatment, the tumor inhibition rates in DOC-NPs 
and DOC-TNPs treated groups were 39.52% and 55.14%, 
respectively (Figure 5A). The DOC-TNPs treated group 
showed the highest antitumor efficiency and the smallest 
tumor volumes (P , 0.01 of 10 mg/kg Taxotere® equal; 
P , 0.01 of 10 mg/kg DOC-NPs equal).
The pathology examination clearly demonstrated the 
significant therapeutic efficacy of DOC-TNPs. The tumors 
in each experimental group were obtained 21 days after 
treatment and the paraffin tumor slices stained by H&E 
were used to evaluate the necrosis levels of tumors. Small 
necrotic regions were observed in the saline, empty PEG-PCL 
and empty PEG-Pep-PCL treated groups (Figure 5B). The 
Taxotere® treated group displayed a larger necrotic region 
surrounded with numerously active cancer cells. A much 
larger necrotic level could be observed in the nanotherapeutic 
groups, especially in the DOC-TNPs treated group.
The real time therapeutic effects of DOC-TNPs, DOC-
NPs and Taxotere® on tumor activity were compared using 
positron emission tomography/computer tomography of 
deoxy-2-[18F]Fluoro-D-glucose (18FDG-PET/CT). The 
advantages of this technique include the visualization and 
quantification of disseminated tumors’ metabolism of tumor 
cells without the need of animal sacrifice for analysis. PET 
scanning images clearly revealed invisible metabolic activity 
within the transplanted tumors of the DOC-TNPs treated 
mice, and CT results confirmed the slowest tumor growth in 
this group. As displayed by Figure 6, the mice treated with 
Taxotere® demonstrated the highest signal intensity, mice 
treated with DOC-NPs and DOC-TNPs presented gradually 
decreased signals. The mean SUVs of tumors in the mice 
that received Taxotere®, DOC-NPs and DOC-TNPs were 
0.83 ± 0.07, 0.47 ± 0.06, 0.20 ± 0.01, respectively. As the 
CT imaging described, the tumor volume of Taxotere® treated 
mice was about 1000 mm3, while the tumors of DOC-NPs 
and DOC-TNPs treated groups were smaller, about 500 and 
300 mm3, respectively.
Discussion
PEG-Pep-PCL nanoparticles, which contained the active 
peptide substrates of gelatinases, were prepared to improve 
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Figure 4 In vivo NIRF images of H22 tumor bearing mice following intravenous 
administration of NIR-797 labeled DOC-NPs and DOC-TNPs during 72 hours. The 
tumors were marked by arrows.
Abbreviations:  DOC-NP,  docetaxel-loaded  nanoparticle;  DOC-TNP,  tumor-
targeted  docetaxel-loaded  nanoparticle;  NIR,  near-infrared;  NIRF,  near-infrared 
fluorescent.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
287
Gelatinase-stimuli and docetaxel-loaded poly(ethylene glycol)-poly(ε-caprolactone) nanoparticlesInternational Journal of Nanomedicine 2012:7
delivery of chemotherapeutic agents to tumor tissues and 
cells. We confirmed the gelatinase-responsive PEG-Pep-PCL 
nanoparticles were not only effectively targeted to the tumor 
tissues but also were taken up into tumor cells, and exhibited 
distinguished antitumor potency when they were used to load 
chemotherapeutic agent DOC. To emphasize the superiority 
of this nanoparticle, the PEG-PCL nanoparticles without 
targeting peptide were compared as the control. The PEG-
Pep-PCL nanoparticles not only kept the passively   targeted 
advantages of common nanocarriers, but also overcame some 
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Figure 5 In vivo antitumor effects of different groups. (A) The tumor growth curves of H22 tumor-bearing mice that received different treatments. The same DOC dose 
(10 mg/kg) was given by intravenous injection on days 1, 7 and 13 (marked by arrows). For Taxotere®, DOC-NPs and DOC-TNPs. **P , 0.01 versus Taxotere® treated 
group or DOC-NPs group. (B) H&E stained slices of tumors from mice on the day 21 at the end of treatment with saline (a), empty PEG-PCL nanoparticles (b), empty PEG-
Pep-PCL nanoparticles (c), Taxotere® (d) (10 mg/kg), DOC-NPs (e) (10 mg/kg DOC equal), DOC-TNPs (f) (10 mg/kg DOC equal) (×40).
Abbreviations: DOC, docetaxel; DOC-NPs, docetaxel-loaded nanoparticles; DOC-TNPs, tumor-targeted docetaxel-loaded nanoparticles; H&E, hematoxylin and eosin; 
PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide.
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Figure 6 PET/CT images of mice administered 100 µCi of 18F-FDG and scanned 30 minutes post injection. From up to down, CT, PET and fusion views. (A) Taxotere® 
(10 mg/kg DOC equal). (B) DOC-NPs (10 mg/kg DOC equal). (C) DOC-TNPs (10 mg/kg DOC equal).
Abbreviations: CT, computed tomography; DOC, docetaxel; DOC-NPs, docetaxel-loaded nanoparticles; DOC-TNPs, tumor-targeted docetaxel-loaded nanoparticles; 
PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide; PET, positron emission tomography.
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shortcomings of PEGylation. That is why PEG-TNPs showed 
high tumor growth suppression.
MMPs have received great attention in cancer research 
due to their important role in cancer progression. A variety 
of small-molecular MMPs inhibitors are under clinical   trials 
or have been developed. However, few MMP inhibitors 
(MMPIs) are used clinically.26,27 The anticancer effects of 
MMPIs are mainly based on blocking either MMPs activity 
or secretion but the functions of MMPs are complex and 
variable. Some MMPs can accelerate tumor progression 
while others are protective. Specific MMPs even exhibit 
both positive and negative functions at different stages of 
the same disease. That’s why the use of MMPIs in multiple 
clinical trials has often been aborted due to severe side-
effects. We need to rethink how to better use MMPs in 
cancer therapeutics. As drug-activators for tumor therapeutic 
strategies, gelatinases have their own advantages. Firstly, 
instead of MMPs inhibitors disturbing the proteases synthe-
sis, activity and function, the enzyme-responsive strategy 
just takes advantage of the hydrolytic functions of MMPs. 
The gelatinase-stimuli strategy can avoid the bottleneck 
in the development of MMPs inhibitors. Secondly, among 
various MMPs, gelatinases are significantly up-regulated 
in various malignant tumors, while almost undetectable in 
non-pathological environments. MMPs-stimuli strategy will 
exhibit superior antitumor effects with limited side effects 
on a number of cancers. Thirdly, gelatinases are widely 
known as tumor associated malignant enzymes and they are 
susceptible to recognize and hydrolyze IV collagen, a major 
component of the extracellular matrix (ECM). It is known 
that the ECM is the first barrier for invasive and metastasis 
tumor cells to overcome. Therefore, the gelatinase-stimuli 
strategy may present its advantages on primary tumors as 
well as micrometastatic or disseminated tumors.
During the past couple of years, PEGylation has 
been widely used in the development of intravenously 
injected drug delivery system.28 PEGylation prolongs 
blood circulation, increases tumor accumulation, reduces 
serum protein adherence and creates a stealth surface to 
avoid the uptake by the reticuloendothelial systems (RES). 
PEGylated nanoparticles are also preferable with good 
biocompatibility, biodegradability, low antigenicity, and 
immunogenicity. However, recent work reported that the 
introduction of PEG chains on the surface of copolymers 
decreased endocytosis and hindered incorporation of  into 
cells.23,29,30 In our cellular uptake studies, the gelatinase-
stimuli strategy improved the low uptake of PEGylated 
nanoparticles in both attached and suspended cancer 
cells, and the added value depended on the gelatinases’ 
expression. This   phenomenon may be ascribed to the deP-
EGylation caused by gelatinases. The gelatinases degraded 
the specific substrates, the linkers of hydrophilic PEG, and 
hydrophobic PCL blocks. The PEG conjugates were cleaved 
and the remaining PCL blocks gathered together for high 
hydrophobicity. The resulting PEG-uncoated nanoparticles 
had a higher affinity for cells than PEGylated nanoparticles, 
inducing more nanoparticles to enter tumor cells. Walker 
et al and Lee et al found such a trend in case of pH-triggering 
PEGylated-liposome and quantum dots (QD) with MMP-2 
cleavage PEG conjugates.31,32 The enhanced cellular uptake 
of PEG-Pep-PCL nanoparticles is important for ideal 
therapeutic efficiency.
The gelatinases-stimuli DOC-TNPs, which could be 
transformed by both MMP-2 and MMP-9, showed dis-
tinguished tumor distribution dominance and antitumor 
efficiency over non-targeting DOC-NPs. Considering the 
synthesis feasibility and targeting specificity, we chose 
PVGLIG, a sequence with gelatinase selectivity, which has 
never been reported by other drug delivery studies,33 as the 
bridge substrate of PEG and PCL blocks. Although, previ-
ous studies confirmed that MMP-2 cleavable liposomes 
could improve gene silencing effect.34,35 There remain many 
challenges in the protease-activatable area, including limited 
systemic evaluation and successful in vivo reports. The in 
vivo NIRF imaging clearly signified the gelatinases-stimuli 
profile altered the distribution of nanoparticles. The PEG-
Pep-PCL nanoparticles can target and deliver to tumor tissues 
through EPR effect and PEGylation. Once arriving at the 
tumor tissues, the PEG conjugates were cleaved by tumor 
gelatinases and the PEG-uncoated particles aggregated. The 
gaps of tumor blood vessels are about 10–1000 nm,36,37 and 
larger particles are not easily extracted from tumor tissues. 
The penetration of nanoparticles is seriously impaired by 
some physiological barriers,38,39 especially the high interstitial 
fluid pressure. Small molecule drugs, such as DOC, diffused 
more easily in tumor tissues than nanoparticles. In vitro drug 
release studies showed gelatinase-stimuli profile induced 
DOC release quickly from PEG-Pep-PCL nanoparticles. This 
means dePEGylated nanoparticles not only induced drug 
accumulation in the tumors, but also delivered more drugs 
to tumor parenchyma and enhanced their efficacy. DOC-
TNPs would enhance the distribution of the delivered drugs 
in the tumors and eradicate the tumors more completely. In 
the meantime, the nanoparticles that are accumulated in the 
liver and other tissues are able to clear, implying minimal 
side effects from these drugs.
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Recent studies also found repeated injections of the 
conventional and noncleavable PEGylated nanoparticles 
could result in the “accelerated blood clearance (ABC)” 
phenomenon, which decreases antitumor effects and increase 
side effects.40,41 During the antitumor study, different DOC 
formations were given three times. As time went on, the 
  difference of antitumor efficacy between DOC-TNPs and 
DOC-NPs became more obvious. Body weight variations, 
blood chemistry test and H&E-stained sections of main 
organs were also done to evaluate the adverse effects of dif-
ferent docetaxel formations (Figure S6 in the “Supplemental 
data”). The body weights in the group receiving DOC-NPs 
showed a remarkable loss compared with DOC-TNPs, espe-
cially on the last few days of the experiment. More recently, 
PEG-cleavage work42,43 showed that cleavable PEG derivatives 
on nanocarriers surface can weaken or eliminate the ABC 
phenomenon by reducing accumulation in liver and spleen. 
It is a clue for our design of the PEG-Pep-PCL nanoparticles, 
which should show similar effect on the ABC phenomenon. 
In fact, the data of the in vivo biodistirbution of fluorescent 
nanoparticles show that the PEG-cleaved DOC-TNPs had less 
accumulation both in liver and spleen compared with DOC-
NPs, indicating the gelatinases-specific strategy can improve 
pharmacokinetic and pharmacodynamic profiles. Thus, the 
gelatinase-cleavage of PEG could minimize or eliminate the 
shortages caused by ABC phenomenon.
This article is focused on the advantages of PEG-
Pep-PCL nanoparticles in the tumor targeting and cellular 
uptake. Therefore, we concentrated on the gelatinase-stimuli 
property and the biodistribution of nanoparticles. As the 
current platform can be universally applied to almost any 
malignant tumors, and is adaptable to load a wide range 
of anticancer drugs, work on choosing the most suitable 
  chemotherapy agents and animal models is currently 
underway and will likely demonstrate the techniques 
  thoroughly. Consequently, the antitumor superiority of DOC-
TNPs is associated with the following factors: (1) superior 
intracellular drug delivery; (2) maximal   accumulation, delay 
and release in tumors; (3) reduced toxicity to other organs 
and tissues; (4) maintenance of the “passive targeting” 
advantages of nanoparticles.
Conclusion
In this paper, the gelatinase-stimuli PEG-Pep-PCL nanopar-
ticles were prepared through inserting the enzyme-specific 
substrate between PEG and PCL blocks. Compared with 
PEG-PCL nanoparticles, the gelatinases strategy overcame 
some shortcomings of PEGylation, mediated specific, 
and sufficient interactions with cancer cells and maximum 
nanoparticles distribution. In tumors, the convertible PEG-
Pep-PCL nanoparticles entered tumor cells more easily 
than PEG-PCL nanoparticles by the dePEGylation of 
gelatinases. In vivo NIRF imaging revealed that DOC-TNPs 
have prominent tumor targeting ability. The PEG-Pep-PCL 
nanoparticles kept high tumor concentration at 72 h pi, while 
PEG-PCL nanoparticles were almost completely excreted 
from the mice. More importantly, the DOC-TNPs showed 
higher antitumor efficacy and lower toxicity than Taxotere®, 
DOC-NPs by the tumor volumes observation, histological 
staining as well as PET/CT imaging. These results imply 
that the PEG-Pep-PCL drug delivery system will provide a 
promising strategy to improve clinical cancer therapy while 
minimizing side effects.
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Materials and methods
Docetaxel and Taxotere® were kindly provided by Jiangsu 
Hengrui Medicine Company (Jiangsu, China). RPMI 1640 
and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide) were purchased from Sigma Chemical 
Company (St Louis, MO). Murine hepatic carcinoma cell 
line H22 and human colon carcinoma cell line LOVO were 
purchased from Shanghai Institute of Cell Biology (Shang-
hai, China).
Particle size and morphology 
characterization
1H-NMR spectra were recorded on an AVANCE 300 MHz 
spectrometer (Bruker, Germany) using chloroform-d1 as 
solvent sparately in 5 mm NMR tubes. In all the spectra 
tetramethylsilane (TMS) was used as the internal reference.
The nanoparticles were suspended in distilled water 
to achieve an appropriate level of scattering. Particle size 
and polydispersity of PEG-Pep-PCL and PEG-PCL were 
  measured by dynamic light scattering (DLS) using a 
Brookhaven BI-9000 AT system (Brookhaven Instruments 
Corporation, Long Island, NY). Each sample was diluted to 
filtered water and measured for three times.
Drug loading content and encapsulation 
efficiency
The lyophilized Doc-loaded nanoparticles were dissolved 
in methanol (HPLC grade, Merck Sharp and Dohme, 
Whitehouse Station, NJ) and sonicated for 15 minutes, cen-
trifuged at 1200 g for 5 minutes. The supernatant fractions 
were prepared for HPLC analysis.
Chromatographic separation was achieved using a HC-C18 
column (250 × 4.6 mm, 5 µm), (Agilent Technologies, Palo 
Alto, CA) at 35°C. The mobile phase consisted of 50/50 
double-distilled water (Millipore, Milford, MA)/acetonitrile 
(HPLC grade, Merck Sharp and Dohme). The flow rate was 
set to 1.0 mL/minute, UV detection wavelength was 230 nm. 
The retention time of DOC was about 3.4 minutes. The drug 
loading content and encapsulation efficiency were calculated 
by equations (1) and (2), respectively.
 
Drug loading content %
Weight of the drug in nanoparticles
=
W Weight of the nanoparticles
 
100%  ×
  (1)
Encapsulation efficiency % 
Weight of the drug in nanopart
=
i icles
Weight of the feeding drug
 100%  ×
  (2)
Gelatin zymography
Gelatin zymography was used to quantify the active 
MMP-2 and MMP-9 extracellular levels. Briefly, 100 µL 
culture medium was subjected to SDS-PAGE in a gel 
containing 10 mg/mL of gelatin. The gels were then 
incubated in 2.5% Triton X-100 for 2 hours and rinsed 
in nanopure distilled H2O. Gels were further incubated at 
37°C for 24 hours in 200 mM NaCl, 5 mM CaCl2, 0.02% 
Brij-35, 50 mM Tris-HCl buffer (pH 8.8), 1 µM ZnCl2, 
then stained with 0.2% Coomassie brilliant blue R-250, 
and destained in 10% acetic acid and 30% methanol in 
H2O. Gelatinolytic activity was detected as unstained 
bands on a blue background. Three independent experi-
ments were performed.
Immunohistochemistry
Tumor samples fixed in 10% neutral buffered formalin 
were embedded in paraffin using automatic embedding 
equipment, after which 5-Am sections were prepared. 
  Immunohistochemical analysis for MMP-9 and MMP-2 was 
done on paraffin-embedded H22 tumor sections of mice.
Side effects study
On Day 21 after treatment, the tissues including tumor, liver, 
spleen, lung, kidney and heart from the tested groups treated 
were dissected and fixed in 10% neutral buffered formalin. 
The tissues were processed routinely into paraffin, sectioned 
at a thickness of 5 µm, stained with H&E, and examined by 
optical microscope. The blood biochemistry and weights of 
all tested mice were also scrutinized.
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Peptide
Figure S2 1H nuclear magnetic resonance spectra (300 MHz, 25°C) of polymers in CDCl3: (A) PEG-Pep-PCL copolymers; (B) PEG-PCL copolymers.
Note: The insert in (A) shows the proton signal from methyl groups in peptide (0.816–1.032 ppm), thus indicating portions of peptide were successfully conjugated into 
the copolymers.
Abbreviations: PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide.
Table S1 Characterization of the DOC-TNPs and DOC-NPs
Nanoparticles Diameter (nm) Polydispersity  
index
Drug loading  
content (%)
Drug encapsulation   
efficiency (%)
DOC-TNP 85.7 0.131 20.3 80.7
DOC-NP 89.9 0.140 19.0 75.7
Abbreviations: DOC-NP, docetaxel-loaded nanoparticle; DOC-TNP, tumor-targeted docetaxel-loaded nanoparticle.
Peptide (PVGLIG) PEG-Pep 
Leu ε-CL
PEG-Pep
PEG-Pep-PCL
O
O
O
O
O O O
O O
OH
O
N
N
N
N
H
N
H
N
H N
H
N
H N
H
N
H
N
H N
H N
H
N
H
N
H
H
N
H
N
H
N
H
N
H
N H
N
H
N H
N
H
N
n
n
n
H3CO
H3CO
H3CO
O
O
O O O
O
O O
O
O O
O
O
O
O O
O
m
O
OH
m
OH
O O
OH
+
+
+
O
O
O
O
O
O
O
O
O
O
O
O O
OH
OH
m
OH EDC/NHS
EDC/NHS
m
O
N
H
N
H
N
H N
H HOOC HOOC
N
H
N
H
N
H
N
H
N
n
H3CO
H2N
H2N
H2N
NH2
Sn(OCt)2 NH2
PEG-NHS
PCL-NH2
PCL-NH2 PCL-HOOC
A
B
C
Figure S1 Synthesis scheme of PEG-Pep-PCL copolymers.
Abbreviations: PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide.
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Abbreviations: DOC, docetaxel; DOC-NPs, docetaxel-loaded nanoparticles; DOC-TNPs, tumor-targeted docetaxel-loaded nanoparticles; PCL, poly(ε-caprolactone); PEG, 
poly(ethylene glycol); Pep, peptide.
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Figure S6 (A) Body weight curves of each group during the whole experiment. (B) Blood chemistry ALT and AST test was performed on Day 21 after initiation of the 
treatment. (C) Blood chemistry BUN and Cr test was performed on Day 21 after initiation of the treatment. (D) Abnormal damage was not observed in the H&E stained 
sections of main organs (×40). The result was consistent with the normal hepatic enzyme levels measured in the blood test (a) saline; (b) empty PEG-PCL nanoparticles;   
(c) empty PEG-Pep-PCL nanoparticles; (d) Taxotere®; (e) DOC-NPs; (f ) Doc-TNPs.
Abbreviations: ALT, alamine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; DOC-NP, docetaxel-loaded nanoparticle; 
DOC-TNP, tumor-targeted docetaxel-loaded nanoparticle; H&E, hematoxylin and eosin; PCL, poly(ε-caprolactone); PEG, poly(ethylene glycol); Pep, peptide.
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